IRADIMED CORP Files 8-K on Financials
Ticker: IRMD · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1325618
| Field | Detail |
|---|---|
| Company | Iradimed CORP (IRMD) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: IRMD
TL;DR
IRADIMED CORP filed an 8-K on Feb 13, 2025, updating on financials.
AI Summary
On February 13, 2025, IRADIMED CORP filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This filing indicates IRADIMED CORP is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and results of operations, with no immediate negative or positive indicators presented in the excerpt.
Key Players & Entities
- IRADIMED CORP (company) — Registrant
- February 13, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 73-1408526 (identifier) — IRS Employer Identification No.
- 1025 Willa Springs Dr. (address) — Principal executive offices
- Winter Springs (city) — Principal executive offices
- FL (state) — Principal executive offices
- 32708 (zip_code) — Principal executive offices
- 407-677-8022 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for IRADIMED CORP?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The filing was reported on February 13, 2025.
In which state was IRADIMED CORP incorporated?
IRADIMED CORP was incorporated in Delaware.
What is the principal executive office address for IRADIMED CORP?
The principal executive office is located at 1025 Willa Springs Dr., Winter Springs, FL 32708.
What is the telephone number provided for IRADIMED CORP?
The telephone number provided is (407) 677-8022.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-02-13 08:30:12
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Capital Market Item 2
Filing Documents
- irmd-20250213x8k.htm (8-K) — 36KB
- irmd-20250213xex99d1.htm (EX-99.1) — 255KB
- irmd-20250213xex99d1001.jpg (GRAPHIC) — 10KB
- 0001558370-25-000907.txt ( ) — 440KB
- irmd-20250213.xsd (EX-101.SCH) — 3KB
- irmd-20250213_lab.xml (EX-101.LAB) — 15KB
- irmd-20250213_pre.xml (EX-101.PRE) — 10KB
- irmd-20250213x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, IRADIMED CORPORATION issued a press release (the "Press Release") announcing its financial results for the quarter ended December 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated February 13, 2025. 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: February 13, 2025 By: /s/John Glenn Name: John Glenn Title: Chief Financial Officer